Shanghai, China, 12 December 2024 –The VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty®), the second-generation transcatheter aortic valve implantation (TAVI) solution from MicroPort® CardioFlow, has recently received marketing approval from the Korean Ministry of Food and Drug Safety (MFDS) (Registration No.: 수허 24-268 호).
VitaFlow Liberty® is the world’s only electric retrievable TAVI system. Building on the design strengths of its predecessor VitaFlow®, it incorporates a hybrid-density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These features provide high radial support, enhance coaxial release, and significantly reduce the incidence of post-procedural paravalvular leaks.
Furthermore, its groundbreaking upgraded delivery system features a unique double-reinforced spiral structure, enabling rapid, stable, and precise release and retrieval. This system also achieves flexibility, with the ability to bend the valve segment 360°, further enhancing surgical precision and adaptability.
The VitaFlow® series TAVI solution, along with its accessory, the Alwide® series Balloon Catheter (Alwide® Plus), has been adopted by more than 700 hospitals across 20 countries and regions, benefiting over 10,000 patients with aortic valve diseases worldwide.
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation; HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow's self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic Research and Development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.en.cardioflowmedtech.com